Harlan Waksal bought $74k of LYRA
Executive Chair at Lyra Therapeutics, Inc.. 25,000 shares at an average of $2.96, traded Nov 10, 2023, filed Nov 13, 2023.
Score components
- +20RoleChair
- +8Trade size$74k at market
- +3Relative to holdingsHoldings up 11%
- +8Price context38% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +32.6%, 3m +63.4%, 6m -87.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-23-063137, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 10, 2023 | POpen-market purchase Common Stock | +25,000 | $2.96 | $74k | 261,966 | Nov 13, 2023 |
Related signals
Other insiders at Lyra Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | Lyra Therapeutics, Inc. | Jason Cavalier Chief Financial Officer | $2,587 769 shares | -0% | |
| 13Weak | Lyra Therapeutics, Inc. | Maria Palasis President & CEO | $5,726 1,702 shares | -0% | |
| 34Weak | LYRAsell Lyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $183k 45,875 shares | -28% | |
| 37Weak | LYRAsell Lyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $344k 70,390 shares | -31% | |
| 10Weak | Lyra Therapeutics, Inc. | Jason Cavalier Chief Financial Officer | $6,094 684 shares | -0% | |
| 13Weak | Lyra Therapeutics, Inc. | Maria Palasis President & CEO | $14k 1,565 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.